I-Mab(US:IMAB)2026-03-11 13:02NovaBridge Biosciences Conference Call Summary Company Overview - Company Name: NovaBridge Biosciences (formerly I-Mab) - Industry: Biotechnology - Focus: Transitioned from an asset-based biotech company to a platform company aimed at bringing Chinese innovations to global markets [2][3] Key Points Business Transformation and Strategy - Name Change: The company rebranded from I-Mab to NovaBridge to reflect its new strategy [2] - Strategic Pivot: Shifted focus to leverage the Chinese biotech ecosystem for global innovation, recognizing the increase in in-licensing deals from 10% to 40% over three years [3] - Competitive Advantage: NovaBridge combines strong access to the Chinese biotech ecosystem with established operations in the U.S., differentiating it from many competitors [5][6] Givastomig Development - Clinical Data: Givastomig shows promising results in combination with Nivolumab and chemotherapy for gastroesophageal adenocarcinoma, with a progression-free survival (PFS) of approximately 17 months, significantly better than existing treatments [11][15] - Efficacy Consistency: The data shows consistent objective response rates of 70%-80% across various patient subgroups [15][16] - Comparison with Competitors: Givastomig's PFS is superior to other treatments like CheckMate 649 (7.7 months) and SPOTLIGHT (10.5 months) [15][16] - Safety Profile: The treatment has a manageable toxicity profile, with gastritis being the only notable side effect [11][19] Future Development Plans - Clinical Trials: Plans to conduct randomized trials to validate the efficacy of Givastomig, addressing concerns about single-arm study limitations [15][30] - Patient Stratification: Future studies will focus on patients with claudin 18.2 expression levels of 1% or greater, ensuring a representative patient population [26][29] VIS-101 Update - Clinical Data: VIS-101 demonstrated favorable safety and efficacy, with two-thirds of patients remaining treatment-free for four months and half for six months, outperforming Vabysmo [42][43] - Mechanism of Action: The molecule targets VEGF-A and Ang2, showing a twofold improvement in VEGF-A and a 17-fold improvement in Angiopoietin-2 binding affinity compared to competitors [50][51] IPO Plans - Hong Kong IPO: The company is adjusting its IPO plans due to regulatory requirements, aiming for a valuation that reflects its pipeline's inherent value before proceeding [60] Market Competition - Competitive Landscape: The gastric cancer treatment market is becoming increasingly competitive, with multiple companies developing similar therapies. NovaBridge aims to position Givastomig as a best-in-class option [30][34] Additional Insights - Regulatory Engagement: Positive interactions with the FDA regarding Givastomig's development strategy indicate strong regulatory support [34] - Future Innovations: The company is exploring novel bispecific and tri-specific agents to enhance its therapeutic offerings [38] Conclusion NovaBridge Biosciences is strategically positioned to leverage its unique access to the Chinese biotech ecosystem while developing promising therapies like Givastomig and VIS-101. The company is focused on rigorous clinical validation and regulatory engagement to ensure successful market entry and competitive positioning in the biotechnology landscape.